progression-free survival
Figure 4 · Panel A
Panel A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Ashraf Badros, Laahn Foster, Larry D Anderson, Chakra P Chaulagain, Erin Pettijohn, Andrew J Cowan, Caitlin Costello, Sarah Larson, Douglas W Sborov, Kenneth H Shain, Rebecca Silbermann, Nina Shah, Alfred Chung, Maria Krevvata, Huiling Pei, Sharmila Patel, Vipin Khare, Annelore Cortoos, Robin Carson, Thomas S Lin, Peter Voorhees
Blood 145(3) 300-310
No randomized trial has directly compared daratumumab and lenalidomide (D-R) maintenance with standard-of-care lenalidomide (R) alone after transplant. Herein, we report the primary results of the phase 3 AURIGA study evaluating D-R vs R maintenance in patients with newly diagnosed multiple myeloma (NDMM) who had very good or better partial response, were minimal residual disease (MRD)-positive (10-5) and anti-CD38-naïve after transplant. Two hundred patients were randomly assigned (1:1) to D-R (n = 99) or R (n = 101) maintenance for up to 36 cycles. The MRD-negative (10-5) conversion rate by 12 months from start of maintenance (primary end point) was significantly higher for D-R than R (50.5% vs 18.8%; odds ratio [OR], 4.51; 95% confidence interval [CI], 2.37-8.57; P < .0001). MRD-negative (10-6) conversion rate was similarly higher with D-R (23.2% vs 5.0%; OR, 5.97; 95% CI, 2.15-16.58; P = .0002). At median follow-up (32.3 months), D-R achieved a higher overall MRD-negative (10-5) conversion rate (D-R, 60.6% vs R, 27.7%; OR, 4.12; 95% CI, 2.26-7.52; P < .0001) and complete response rate or better (75.8% vs 61.4%; OR, 2.00; 95% CI, 1.08-3.69; P = .0255) vs R. Progression-free survival (PFS) favored D-R vs R (hazard ratio, 0.53; 95% CI, 0.29-0.97); estimated 30-month PFS rates were 82.7% for D-R and 66.4% for R. Incidences of grade 3/4 cytopenias (54.2% vs 46.9%) and infections (18.8% vs 13.3%) were slightly higher with D-R than R. In conclusion, D-R maintenance achieved a higher MRD-negative conversion rate and improved PFS after transplant vs R, with no new safety concerns. This trial was registered at www.clinicaltrials.gov as #NCT03901963.
1 个 Figure · 2 个 KM 面板
Figure 4. PFS analysis. PFS analysis in the ITT population∗ overall (A) and by MRD-negative (10 –5 ) conversion status by 12 months (B). † Estimated 30-month PFS rates are shown. ∗At a median follow-up of 32.3 months, median PFS was 37.9 months in the D-R group and was not reached in the R group. †MRD-negative by 12 months refers to patients who were MRD-positive at baseline and achieved MRD-negative status (at a threshold of 10 –5 ) by bone marrow aspirate from randomization to 12 months (+2-month window), but before progressive disease and subsequent antimyeloma therapy. Otherwise, patients were considered MRD-positive. ‡Per study protocol, disease assessments stopped at the end of study treatment (cycle 36), after which patients were only followed for survival. At the time of this analysis, the number of patients who reached the end of study treatment was low, thus resulting in a low number of patients at risk. Two D-R events occurred at the tail end of study assessments: 1 reported at 1134 days (37.26 months) and 1 at 1153 days (37.88 months). Because of these events, there was a sudden and steep drop in the Kaplan-Meier curve for D-R. ITT, intent to treat.
Figure 4 · Panel A
Panel A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 · Panel B
Panel B 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。